13F Holdings
中文EN

KTTA Pasithea Therapeutics Corp.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1841330 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-84.0%
TTM EPS YoY68.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-88.8%
ROA-82.6%
ROIC (approx.)-414.6%
Asset turnover—

Leverage & solvency

Liabilities / assets5.9%
Debt / equity0.00x
Current ratio15.67x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.78x
Accruals ratio-18.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue———$486,559$15,062
Cost of revenue———$113,195$17,275
Gross profit———$373,364-$2,213
R&D expense$7.98M$7.20M$8.10M$2.67M—
SG&A expense$12.88M$7.05M$7.88M$9.92M$4.51M
Operating income-$20.86M-$14.25M-$15.98M-$12.59M-$4.51M
Interest expense———$102$508
Pretax income-$20.43M-$13.90M-$15.51M-$11.73M-$2.17M
Net income-$20.43M-$13.90M-$15.96M-$13.94M-$2.17M
EBITDA-$20.82M-$14.23M-$15.96M-$12.58M-$4.51M
EPS (basic)-2.91-12.69-0.42-1.76-0.21
EPS (diluted)-2.91-12.69-0.42-1.76-0.21
Weighted avg. shares (diluted)7.03M1.10M1.23M1.26M10.40M
Banking
Net interest income————-$508
Balance sheet
Cash & equivalents$55.16M$6.92M$16.33M$33.09M$52.90M
Current assets$56.46M$7.37M$16.69M$34.08M$53.30M
PP&E, net—$122,343$141,208$125,197$20,124
Goodwill—$1.26M$1.26M$1.26M—
Intangibles$2.90M$7.31M$7.94M$8.57M—
Total assets$60.24M$16.06M$26.12M$45.18M$53.32M
Current liabilities$4.97M$1.12M$2.63M$1.88M$447,280
Total liabilities$5.02M$1.28M$2.72M$2.68M$1.90M
Shareholders' equity$55.22M$14.78M$23.40M$42.50M$51.42M
Shares outstanding23.09M1.39M1.04M1.30M23.01M
Cash flow statement
Operating cash flow-$15.21M-$13.92M-$12.81M-$11.89M-$3.17M
Capital expenditure——$34,301$107,101$21,503
Free cash flow——-$12.85M-$12.00M-$3.20M
Investing cash flow$11,000—$75,199-$2.30M-$21,503
Financing cash flow$63.52M$4.52M-$3.73M-$3.21M$55.93M
Depreciation & amortization$32,421$18,865$18,290$5,094$1,379
Stock-based compensation$297,467$773,693$592,269$835,064$471,250
Share buybacks——$3.73M——

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.